{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T13:50:07Z","timestamp":1792245007826,"version":"4.4.0"},"reference-count":151,"publisher":"The Endocrine Society","issue":"6","license":[{"start":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T00:00:00Z","timestamp":1752192000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Acromegaly is a chronic systemic disease associated with considerable morbidity due to its many complications, which lead to increased mortality rates. Adequate treatment is essential to reduce the development of long-term complications and to restore mortality rates to those of the general population. Three modalities of treatment are currently available (surgery, medical therapy, and radiotherapy). Surgery is considered the first-line treatment and achieves disease cure in approximately 50% of patients in reference centers. Three drug classes are currently available (somatostatin receptor ligands, dopamine agonists, and growth hormone receptor antagonists); however, disease control is not achieved in a considerable proportion of patients (\u223c40%). Despite substantial advances in medical therapy over the last few decades, the treatment burden is still high, and quality of life is not fully restored in many patients, even when biochemical control is achieved. Therefore, the development of medications with greater efficacy and\/or easier and more convenient administration is an unmet need in the treatment of acromegaly. In addition, shifting from the current trial-and-error approach to a more precise treatment strategy guided by biomarkers predictive of the response to different medical therapies will optimize and improve patient outcomes. In this review, current treatments as well as new drugs in different phases of development are detailed, and the role of precision medicine in the treatment of acromegaly is discussed.<\/jats:p>","DOI":"10.1210\/endrev\/bnaf020","type":"journal-article","created":{"date-parts":[[2025,7,11]],"date-time":"2025-07-11T17:24:36Z","timestamp":1752254676000},"page":"838-855","source":"Crossref","is-referenced-by-count":24,"title":["Medical Treatment of Acromegaly: Navigating the Present, Shaping the Future"],"prefix":"10.1210","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9250-3558","authenticated-orcid":false,"given":"M\u00f4nica R","family":"Gadelha","sequence":"first","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]},{"name":"Neuroendocrine Unit, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20230-140 ,","place":["Brazil"]},{"name":"Neuropathology and Molecular Genetics Laboratory, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20231-092 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luiz Eduardo","family":"Wildemberg","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]},{"name":"Neuroendocrine Unit, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20230-140 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nelma Veronica","family":"Marques","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Kasuki","sequence":"additional","affiliation":[{"name":"Neuroendocrinology Research Center, Endocrinology Section, Medical School and Hospital Universit\u00e1rio Clementino Fraga Filho, Universidade Federal do Rio de Janeiro , Rio de Janeiro 21941-913 ,","place":["Brazil"]},{"name":"Neuroendocrine Unit, Instituto Estadual do C\u00e9rebro Paulo Niemeyer, Secretaria Estadual de Sa\u00fade , Rio de Janeiro 20230-140 ,","place":["Brazil"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2025,7,11]]},"reference":[{"issue":"2","key":"2025112318514747900_bnaf020-B1","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1210\/jc.2003-031199","article-title":"Factors influencing mortality in acromegaly","volume":"89","author":"Holdaway","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 5","key":"2025112318514747900_bnaf020-B2","first-page":"166","article-title":"Excess mortality in acromegaly","volume":"68","author":"Holdaway","year":"2007","journal-title":"Horm Res"},{"issue":"1","key":"2025112318514747900_bnaf020-B3","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1210\/jc.2007-1191","article-title":"Mortality in acromegaly: a metaanalysis","volume":"93","author":"Dekkers","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B4","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1210\/er.2018-00115","article-title":"Systemic complications of acromegaly and the impact of the current treatment landscape: an update","volume":"40","author":"Gadelha","year":"2019","journal-title":"Endocr Rev"},{"issue":"6","key":"2025112318514747900_bnaf020-B5","doi-asserted-by":"crossref","first-page":"630","DOI":"10.20945\/2359-3997000000193","article-title":"Determinants of morbidities and mortality in acromegaly","volume":"63","author":"Kasuki","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B6","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1016\/j.ecl.2020.05.007","article-title":"Acromegaly: update on management and long-term morbidities","volume":"49","author":"Kasuki","year":"2020","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"5","key":"2025112318514747900_bnaf020-B7","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1007\/s11102-023-01345-0","article-title":"Pilot study to define criteria for Pituitary Tumors Centers of Excellence (PTCOE): results of an audit of leading international centers","volume":"26","author":"Giustina","year":"2023","journal-title":"Pituitary"},{"issue":"4","key":"2025112318514747900_bnaf020-B8","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s11102-024-01397-w","article-title":"Standards of care for medical management of acromegaly in pituitary tumor centers of excellence (PTCOE)","volume":"27","author":"Giustina","year":"2024","journal-title":"Pituitary"},{"issue":"11","key":"2025112318514747900_bnaf020-B9","doi-asserted-by":"crossref","first-page":"2193","DOI":"10.1007\/s00701-017-3318-6","article-title":"Microsurgical versus endoscopic transsphenoidal resection for acromegaly: a systematic review of outcomes and complications","volume":"159","author":"Chen","year":"2017","journal-title":"Acta Neurochir (Wien)"},{"issue":"4","key":"2025112318514747900_bnaf020-B10","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s11154-020-09588-z","article-title":"Multidisciplinary management of acromegaly: a consensus","volume":"21","author":"Giustina","year":"2020","journal-title":"Rev Endocr Metab Disord"},{"issue":"1","key":"2025112318514747900_bnaf020-B11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s11102-020-01091-7","article-title":"A Pituitary Society update to acromegaly management guidelines","volume":"24","author":"Fleseriu","year":"2021","journal-title":"Pituitary"},{"issue":"3","key":"2025112318514747900_bnaf020-B12","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s12020-018-1590-8","article-title":"Predictors of surgical outcome and early criteria of remission in acromegaly","volume":"60","author":"Antunes","year":"2018","journal-title":"Endocrine"},{"issue":"11","key":"2025112318514747900_bnaf020-B13","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1007\/s00701-016-2903-4","article-title":"Surgical treatment of acromegaly according to the 2010 remission criteria: systematic review and meta-analysis","volume":"158","author":"Starnoni","year":"2016","journal-title":"Acta Neurochir (Wien)"},{"issue":"3","key":"2025112318514747900_bnaf020-B14","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1530\/eje.1.01863","article-title":"The outcome of surgery in 668 patients with acromegaly using current criteria of biochemical \u2018cure\u2019","volume":"152","author":"Nomikos","year":"2005","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"2025112318514747900_bnaf020-B15","doi-asserted-by":"crossref","first-page":"2732","DOI":"10.1210\/jc.2011-0554","article-title":"Endoscopic transsphenoidal surgery for acromegaly: remission using modern criteria, complications, and predictors of outcome","volume":"96","author":"Jane","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B16","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1111\/j.1365-2265.2011.04193.x","article-title":"Acromegaly surgery in Manchester revisited--the impact of reducing surgeon numbers and the 2010 consensus guidelines for disease remission","volume":"76","author":"Wang","year":"2012","journal-title":"Clin Endocrinol (Oxf)"},{"key":"2025112318514747900_bnaf020-B17","doi-asserted-by":"crossref","first-page":"614382","DOI":"10.3389\/fneur.2021.614382","article-title":"A meta-analysis of endoscopic vs. microscopic transsphenoidal surgery for non-functioning and functioning pituitary adenomas: comparisons of efficacy and safety","volume":"12","author":"Guo","year":"2021","journal-title":"Front Neurol"},{"key":"2025112318514747900_bnaf020-B18","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1016\/j.wneu.2016.10.029","article-title":"Endoscopic endonasal versus microsurgical transsphenoidal approach for growth hormone-secreting pituitary adenomas-systematic review and meta-analysis","volume":"97","author":"Phan","year":"2017","journal-title":"World Neurosurg"},{"issue":"4","key":"2025112318514747900_bnaf020-B19","doi-asserted-by":"crossref","first-page":"803","DOI":"10.3171\/2014.12.JNS141083","article-title":"Invasion of the cavernous sinus space in pituitary adenomas: endoscopic verification and its correlation with an MRI-based classification","volume":"122","author":"Micko","year":"2015","journal-title":"J Neurosurg"},{"key":"2025112318514747900_bnaf020-B20","doi-asserted-by":"crossref","first-page":"386401","DOI":"10.1155\/2012\/386401","article-title":"Surgery and radiosurgery for acromegaly: a review of indications, operative techniques, outcomes, and complications","volume":"2012","author":"Marquez","year":"2012","journal-title":"Int J Endocrinol"},{"issue":"5","key":"2025112318514747900_bnaf020-B21","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s11102-017-0838-2","article-title":"Criteria for the definition of Pituitary Tumor Centers of Excellence (PTCOE): a Pituitary Society statement","volume":"20","author":"Casanueva","year":"2017","journal-title":"Pituitary"},{"issue":"6","key":"2025112318514747900_bnaf020-B22","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3171\/2013.8.JNS13224","article-title":"Treatment of acromegaly by endoscopic transsphenoidal surgery: surgical experience in 214 cases and cure rates according to current consensus criteria","volume":"119","author":"Hazer","year":"2013","journal-title":"J Neurosurg"},{"issue":"2","key":"2025112318514747900_bnaf020-B23","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1093\/neuros\/nyx020","article-title":"Long-term endocrine outcomes following endoscopic endonasal transsphenoidal surgery for acromegaly and associated prognostic factors","volume":"81","author":"Babu","year":"2017","journal-title":"Neurosurgery"},{"key":"2025112318514747900_bnaf020-B24","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.wneu.2017.04.141","article-title":"Outcome of endoscopic transsphenoidal surgery for acromegaly","volume":"104","author":"Kim","year":"2017","journal-title":"World Neurosurg"},{"issue":"3","key":"2025112318514747900_bnaf020-B25","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3171\/2021.2.JNS204440","article-title":"Stereotactic radiosurgery for secretory pituitary adenomas: systematic review and International Stereotactic Radiosurgery Society practice recommendations","volume":"136","author":"Mathieu","year":"2022","journal-title":"J Neurosurg"},{"issue":"4","key":"2025112318514747900_bnaf020-B26","doi-asserted-by":"crossref","first-page":"101898","DOI":"10.1016\/j.beem.2024.101898","article-title":"Efficacy and safety of radiosurgery in acromegaly","volume":"38","author":"Albano","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B27","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1093\/neuros\/nyy178","article-title":"Stereotactic radiosurgery for acromegaly: an international multicenter retrospective cohort study","volume":"84","author":"Ding","year":"2019","journal-title":"Neurosurgery"},{"issue":"8","key":"2025112318514747900_bnaf020-B28","doi-asserted-by":"publisher","first-page":"943","DOI":"10.4158\/EP14574.RA","article-title":"Radiotherapy vs. radiosurgery in treating patients with acromegaly: systematic review and meta-analysis","volume":"21","author":"Abu Dabrh","year":"2015","journal-title":"Endocr Pract"},{"issue":"1","key":"2025112318514747900_bnaf020-B29","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1007\/s11102-016-0783-5","article-title":"Updates in outcomes of stereotactic radiation therapy in acromegaly","volume":"20","author":"Gheorghiu","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"2025112318514747900_bnaf020-B30","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1530\/EJE-07-0562","article-title":"Quantitative analysis of somatostatin receptor subtypes (1\u20135) gene expression levels in somatotropinomas and correlation to in vivo hormonal and tumor volume responses to treatment with octreotide LAR","volume":"158","author":"Taboada","year":"2008","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025112318514747900_bnaf020-B31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1007\/s11102-009-0191-1","article-title":"Rapid and sustained reduction of serum growth hormone and insulin-like growth factor-1 in patients with acromegaly receiving lanreotide Autogel therapy: a randomized, placebo-controlled, multicenter study with a 52 week open extension","volume":"13","author":"Melmed","year":"2010","journal-title":"Pituitary"},{"issue":"5","key":"2025112318514747900_bnaf020-B32","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1365-2265.2008.03441.x","article-title":"Octreotide LAR vs. surgery in newly diagnosed patients with acromegaly: a randomized, open-label, multicentre study","volume":"70","author":"Colao","year":"2009","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"3","key":"2025112318514747900_bnaf020-B33","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/s11102-015-0684-z","article-title":"Interpreting biochemical control response rates with first-generation somatostatin analogues in acromegaly","volume":"19","author":"Colao","year":"2016","journal-title":"Pituitary"},{"issue":"1","key":"2025112318514747900_bnaf020-B34","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1007\/s12020-021-02766-2","article-title":"GH and IGF-I levels and tumor shrinkage in response to first generation somatostatin receptor ligands in acromegaly: a comparative study between two reference centers for pituitary diseases in Brazil","volume":"74","author":"Manosso","year":"2021","journal-title":"Endocrine"},{"issue":"5","key":"2025112318514747900_bnaf020-B35","doi-asserted-by":"crossref","first-page":"e36411","DOI":"10.1371\/journal.pone.0036411","article-title":"Meta-analysis on the effects of octreotide on tumor mass in acromegaly","volume":"7","author":"Giustina","year":"2012","journal-title":"PLoS One"},{"issue":"9","key":"2025112318514747900_bnaf020-B36","first-page":"2768","article-title":"Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients-a clinical research center study","volume":"80","author":"Newman","year":"1995","journal-title":"J Clin Endocrinol Metab"},{"issue":"9 Suppl 2","key":"2025112318514747900_bnaf020-B37","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/0026-0495(92)90027-8","article-title":"Gallstones during octreotide therapy","volume":"41","author":"Dowling","year":"1992","journal-title":"Metabolism"},{"issue":"10","key":"2025112318514747900_bnaf020-B38","doi-asserted-by":"crossref","first-page":"e3785","DOI":"10.1210\/clinem\/dgaa526","article-title":"Maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide","volume":"105","author":"Samson","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B39","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/S2213-8587(21)00296-5","article-title":"Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial","volume":"10","author":"Fleseriu","year":"2022","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"2025112318514747900_bnaf020-B40","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1210\/jc.2014-4113","article-title":"Safety and efficacy of oral octreotide in acromegaly: results of a multicenter phase III trial","volume":"100","author":"Melmed","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025112318514747900_bnaf020-B41","first-page":"2338","article-title":"Treatment of prolactin-secreting macroadenomas with the once-weekly dopamine agonist cabergoline","volume":"81","author":"Biller","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025112318514747900_bnaf020-B42","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/cen.13595","article-title":"Treatment escape reduces the effectiveness of cabergoline during long-term treatment of acromegaly in monotherapy or in association with first-generation somatostatin receptor ligands","volume":"88","author":"Kasuki","year":"2018","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"5","key":"2025112318514747900_bnaf020-B43","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1210\/jc.2010-2443","article-title":"Place of cabergoline in acromegaly: a meta-analysis","volume":"96","author":"Sandret","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B44","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s12020-014-0183-4","article-title":"Cabergoline treatment in acromegaly: cons","volume":"46","author":"Kasuki","year":"2014","journal-title":"Endocrine"},{"issue":"9","key":"2025112318514747900_bnaf020-B45","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/BF03348016","article-title":"Use of cabergoline in the long-term treatment of hyperprolactinemic and acromegalic patients","volume":"20","author":"Muratori","year":"1997","journal-title":"J Endocrinol Invest"},{"issue":"3","key":"2025112318514747900_bnaf020-B46","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1007\/s12020-018-1744-8","article-title":"Impulse control disorders in patients with prolactinoma receiving dopamine agonist therapy: a prospective study with 1 year follow-up","volume":"62","author":"Celik","year":"2018","journal-title":"Endocrine"},{"key":"2025112318514747900_bnaf020-B47","doi-asserted-by":"crossref","first-page":"844718","DOI":"10.3389\/fpsyt.2022.844718","article-title":"Binge eating and compulsive buying during cabergoline treatment for prolactinoma: a case report","volume":"13","author":"Correa","year":"2022","journal-title":"Front Psychiatry"},{"issue":"1","key":"2025112318514747900_bnaf020-B48","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1056\/NEJMoa054830","article-title":"Valvular heart disease and the use of dopamine agonists for Parkinson's disease","volume":"356","author":"Zanettini","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"2025112318514747900_bnaf020-B49","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ecl.2014.10.007","article-title":"Cabergoline use for pituitary tumors and valvular disorders","volume":"44","author":"Auriemma","year":"2015","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"4","key":"2025112318514747900_bnaf020-B50","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1517\/14656566.2016.1146688","article-title":"Pasireotide for the treatment of acromegaly","volume":"17","author":"Wildemberg","year":"2016","journal-title":"Expert Opin Pharmacother"},{"issue":"6","key":"2025112318514747900_bnaf020-B51","doi-asserted-by":"crossref","first-page":"2009","DOI":"10.1210\/jc.2017-00135","article-title":"In vitro head-to-head comparison between octreotide and pasireotide in GH-secreting pituitary adenomas","volume":"102","author":"Gatto","year":"2017","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B52","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1210\/clinem\/dgab726","article-title":"The future of somatostatin receptor ligands in acromegaly","volume":"107","author":"Gadelha","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B53","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1210\/jc.2013-2480","article-title":"Pasireotide versus octreotide in acromegaly: a head-to-head superiority study","volume":"99","author":"Colao","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2025112318514747900_bnaf020-B54","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S2213-8587(14)70169-X","article-title":"Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial","volume":"2","author":"Gadelha","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"6","key":"2025112318514747900_bnaf020-B55","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1530\/EJE-19-0762","article-title":"Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study","volume":"182","author":"Colao","year":"2020","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025112318514747900_bnaf020-B56","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1007\/s11102-014-0585-6","article-title":"Pasireotide LAR maintains inhibition of GH and IGF-1 in patients with acromegaly for up to 25 months: results from the blinded extension phase of a randomized, double-blind, multicenter, Phase III study","volume":"18","author":"Sheppard","year":"2015","journal-title":"Pituitary"},{"issue":"2","key":"2025112318514747900_bnaf020-B57","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1007\/s12020-018-1690-5","article-title":"Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study","volume":"62","author":"Shimon","year":"2018","journal-title":"Endocrine"},{"issue":"12","key":"2025112318514747900_bnaf020-B58","doi-asserted-by":"crossref","first-page":"e1571","DOI":"10.1210\/clinem\/dgad378","article-title":"Long-term efficacy and safety of pasireotide in patients with acromegaly: 14 years of single-center real-world experience","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B59","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.diabres.2013.12.011","article-title":"Management of hyperglycemia associated with pasireotide (SOM230): healthy volunteer study","volume":"103","author":"Breitschaft","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"issue":"13","key":"2025112318514747900_bnaf020-B60","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1007\/s40265-016-0615-y","article-title":"Management of hyperglycemia in patients with acromegaly treated with pasireotide LAR","volume":"76","author":"Samson","year":"2016","journal-title":"Drugs"},{"issue":"12","key":"2025112318514747900_bnaf020-B61","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1530\/EC-20-0361","article-title":"Risk factors and management of pasireotide-associated hyperglycemia in acromegaly","volume":"9","author":"Gadelha","year":"2020","journal-title":"Endocr Connect"},{"issue":"10","key":"2025112318514747900_bnaf020-B62","doi-asserted-by":"crossref","first-page":"e230155","DOI":"10.1530\/EC-23-0155","article-title":"Long-term, real-world experience of pasireotide dose reduction in patients with acromegaly","volume":"12","author":"Marques","year":"2023","journal-title":"Endocr Connect"},{"issue":"6","key":"2025112318514747900_bnaf020-B63","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1530\/EJE-18-0616","article-title":"Long-term treatment with pegvisomant: observations from 2090 acromegaly patients in ACROSTUDY","volume":"179","author":"Buchfelder","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025112318514747900_bnaf020-B64","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1590\/2359-3997000000210","article-title":"Experience with pegvisomant treatment in acromegaly in a single Brazilian tertiary reference center: efficacy, safety and predictors of response","volume":"60","author":"Kasuki","year":"2016","journal-title":"Arch Endocrinol Metab"},{"issue":"4","key":"2025112318514747900_bnaf020-B65","first-page":"328","article-title":"Brazilian multicenter study on pegvisomant treatment in acromegaly","volume":"63","author":"Boguszewski","year":"2019","journal-title":"Arch Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1530\/EJE-08-0990","article-title":"Successful use of weekly pegvisomant administration in patients with acromegaly","volume":"161","author":"Higham","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"2025112318514747900_bnaf020-B67","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1590\/S0004-27302011000200001","article-title":"Recommendations of Neuroendocrinology Department from Brazilian Society of Endocrinology and Metabolism for diagnosis and treatment of acromegaly in Brazil","volume":"55","author":"Vieira Neto","year":"2011","journal-title":"Arq Bras Endocrinol Metabol"},{"issue":"4","key":"2025112318514747900_bnaf020-B68","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1530\/EJE-08-0843","article-title":"Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients","volume":"160","author":"Neggers","year":"2009","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025112318514747900_bnaf020-B69","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ghir.2011.03.004","article-title":"Combination treatment with somatostatin analogues and pegvisomant in acromegaly","volume":"21","author":"Neggers","year":"2011","journal-title":"Growth Horm IGF Res"},{"issue":"10","key":"2025112318514747900_bnaf020-B70","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1210\/jc.2014-2032","article-title":"Long-term efficacy and safety of pegvisomant in combination with long-acting somatostatin analogs in acromegaly","volume":"99","author":"Neggers","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B71","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s11102-012-0382-z","article-title":"Pegvisomant and cabergoline combination therapy in acromegaly","volume":"16","author":"Bernabeu","year":"2013","journal-title":"Pituitary"},{"issue":"2","key":"2025112318514747900_bnaf020-B72","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1007\/s12020-015-0810-8","article-title":"Combined treatment of somatostatin analogues with pegvisomant in acromegaly","volume":"52","author":"Franck","year":"2015","journal-title":"Endocrine"},{"issue":"11","key":"2025112318514747900_bnaf020-B73","doi-asserted-by":"crossref","first-page":"5478","DOI":"10.1210\/jc.2019-00825","article-title":"Pasireotide and pegvisomant combination treatment in acromegaly resistant to second-line therapies: a longitudinal study","volume":"104","author":"Chiloiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"2025112318514747900_bnaf020-B74","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1210\/jc.2011-2603","article-title":"Effective combination treatment with cabergoline and low-dose pegvisomant in active acromegaly: a prospective clinical trial","volume":"97","author":"Higham","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B75","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1210\/jc.2017-02017","article-title":"Efficacy and safety of switching to pasireotide in patients with acromegaly controlled with pegvisomant and first-generation somatostatin analogues (PAPE study)","volume":"103","author":"Muhammad","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B76","doi-asserted-by":"crossref","first-page":"101264","DOI":"10.1016\/j.beem.2019.02.001","article-title":"National acromegaly registries","volume":"33","author":"Maione","year":"2019","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B77","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11102-024-01387-y","article-title":"Changes in multi-modality management of acromegaly in a tertiary centre over 2 decades","volume":"27","author":"Amodru","year":"2024","journal-title":"Pituitary"},{"issue":"3","key":"2025112318514747900_bnaf020-B78","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.1210\/clinem\/dgz187","article-title":"Biochemical control in acromegaly with multimodality therapies: outcomes from a pituitary center and changes over time","volume":"105","author":"Ghajar","year":"2020","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B79","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12902-020-00595-4","article-title":"Patient reported outcome data from acromegaly patients treated with injectable somatostatin receptor ligands (SRLs) in routine clinical practice","volume":"20","author":"Geer","year":"2020","journal-title":"BMC Endocr Disord"},{"issue":"2","key":"2025112318514747900_bnaf020-B80","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1007\/s11102-019-01013-2","article-title":"Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider","volume":"23","author":"Geer","year":"2020","journal-title":"Pituitary"},{"issue":"3","key":"2025112318514747900_bnaf020-B81","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1111\/bcp.12698","article-title":"Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers","volume":"80","author":"Tiberg","year":"2015","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"2025112318514747900_bnaf020-B82","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1080\/14737175.2024.2417419","article-title":"The current status of somatostatin analogs in the treatment of neuroendocrine tumors and future perspectives","volume":"25","author":"Lauricella","year":"2025","journal-title":"Expert Rev Neurother"},{"issue":"4","key":"2025112318514747900_bnaf020-B83","doi-asserted-by":"crossref","first-page":"e1323","DOI":"10.1210\/clinem\/dgad568","article-title":"New treatments for acromegaly in development","volume":"109","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B84","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrendo.2015.196","article-title":"New therapeutic agents for acromegaly","volume":"12","author":"Melmed","year":"2016","journal-title":"Nat Rev Endocrinol"},{"key":"2025112318514747900_bnaf020-B85","author":"Roberts"},{"key":"2025112318514747900_bnaf020-B86","doi-asserted-by":"crossref","first-page":"78","DOI":"10.3389\/fendo.2018.00078","article-title":"Novel somatostatin receptor ligands therapies for acromegaly","volume":"9","author":"Paragliola","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"2","key":"2025112318514747900_bnaf020-B87","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00280-018-3734-1","article-title":"Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study","volume":"83","author":"Pavel","year":"2019","journal-title":"Cancer Chemother Pharmacol"},{"issue":"6","key":"2025112318514747900_bnaf020-B88","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1210\/clinem\/dgae707","article-title":"Octreotide subcutaneous depot for acromegaly: a randomized, double-blind, placebo-controlled phase 3 trial, ACROINNOVA 1","volume":"110","author":"Ferone","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"2025112318514747900_bnaf020-B89","author":"Ferone"},{"key":"2025112318514747900_bnaf020-B90","author":"Ferone"},{"issue":"4","key":"2025112318514747900_bnaf020-B91","doi-asserted-by":"crossref","first-page":"101906","DOI":"10.1016\/j.beem.2024.101906","article-title":"Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine","volume":"38","author":"Wildemberg","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B92","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s11102-021-01201-z","article-title":"Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers","volume":"25","author":"Madan","year":"2022","journal-title":"Pituitary"},{"key":"2025112318514747900_bnaf020-B93","author":"Randeva"},{"issue":"5","key":"2025112318514747900_bnaf020-B94","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1210\/clinem\/dgac643","article-title":"ACROBAT edge: safety and efficacy of switching injected SRLs to oral paltusotine in patients with acromegaly","volume":"108","author":"Gadelha","year":"2023","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B95","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1186\/s41687-023-00541-7","article-title":"Development and evaluation of the acromegaly symptom diary","volume":"7","author":"Martin","year":"2023","journal-title":"J Patient Rep Outcomes"},{"issue":"Suppl 1","key":"2025112318514747900_bnaf020-B96","doi-asserted-by":"crossref","first-page":"bvad114.1083","DOI":"10.1210\/jendso\/bvad114.1083","article-title":"OR01-01 Oral, once-daily, paltusotine (non-peptide selective somatostatin receptor subtype 2 agonist) therapy in patients with acromegaly is associated with long-term biochemical and symptom control and is preferred over injectable somatostatin-receptor ligands","volume":"7","author":"Gadelha","year":"2023","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2025112318514747900_bnaf020-B97","doi-asserted-by":"crossref","first-page":"bvae163.1269","DOI":"10.1210\/jendso\/bvae163.1269","article-title":"12531 Long-term safety and efficacy of once-daily oral paltusotine in the treatment of patients with acromegaly: update from acrobat advance","volume":"8","author":"Gadelha","year":"2024","journal-title":"J Endocr Soc"},{"issue":"Suppl 1","key":"2025112318514747900_bnaf020-B98","doi-asserted-by":"crossref","first-page":"A524","DOI":"10.1210\/jendso\/bvab048.1068","article-title":"Pharmacokinetics and safety of an improved oral formulation of paltusotine, a selective, non-peptide somatostatin receptor 2 (SST2) agonist for the treatment of acromegaly","volume":"5","author":"Luo","year":"2021","journal-title":"J Endocr Soc"},{"issue":"1","key":"2025112318514747900_bnaf020-B99","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1210\/clinem\/dgae385","article-title":"Acromegaly disease control maintained after switching from injected somatostatin receptor ligands to oral paltusotine","volume":"110","author":"Gadelha","year":"2024","journal-title":"J Clin Endocrinol Metab"},{"issue":"Suppl 1","key":"2025112318514747900_bnaf020-B100","doi-asserted-by":"crossref","first-page":"bvae163.1201","DOI":"10.1210\/jendso\/bvae163.1201","article-title":"12535 efficacy and safety of once-daily oral paltusotine in medically untreated patients with acromegaly: results from the phase 3, randomized, placebo-controlled pathfndr-2 study","volume":"8","author":"Biller","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025112318514747900_bnaf020-B101","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1530\/EJE-15-0215","article-title":"Lanreotide Autogel 120\u2005mg at extended dosing intervals in patients with acromegaly biochemically controlled with octreotide LAR: the LEAD study","volume":"173","author":"Neggers","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025112318514747900_bnaf020-B102","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1530\/EJE-15-1042","article-title":"Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly","volume":"174","author":"Strasburger","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"12","key":"2025112318514747900_bnaf020-B103","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1080\/17512433.2021.1986004","article-title":"Pharmacological and safety profile of a prolonged-release lanreotide formulation in acromegaly","volume":"14","author":"Neggers","year":"2021","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"3","key":"2025112318514747900_bnaf020-B104","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12020-020-02424-z","article-title":"Effectiveness of lanreotide autogel 120 mg at extended dosing intervals for acromegaly","volume":"70","author":"Bernab\u00e9u","year":"2020","journal-title":"Endocrine"},{"issue":"3","key":"2025112318514747900_bnaf020-B105","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1055\/s-0030-1267244","article-title":"Efficacy and acceptability of lanreotide Autogel\u00ae 120\u2005mg at different dose intervals in patients with acromegaly previously treated with octreotide LAR","volume":"119","author":"Schopohl","year":"2011","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"2025112318514747900_bnaf020-B106","year":"2025"},{"key":"2025112318514747900_bnaf020-B107","author":"Bellon"},{"key":"2025112318514747900_bnaf020-B108","author":"Ispas-Jouron"},{"issue":"3","key":"2025112318514747900_bnaf020-B109","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1093\/ejendo\/lvaf043","article-title":"Additive effects of ALXN2420, a GH receptor antagonist, and octreotide on IGF1 suppression in vivo","volume":"192","author":"Ravel","year":"2025","journal-title":"Eur J Endocrinol"},{"key":"2025112318514747900_bnaf020-B110","doi-asserted-by":"crossref","first-page":"bvae163.1100","DOI":"10.1210\/jendso\/bvae163.1100","article-title":"A phase 1 clinical study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of AZP-3813, a novel, small peptide growth hormone receptor antagonist, in healthy subjects","volume":"8","author":"Allas","year":"2024","journal-title":"J Endocr Soc"},{"issue":"3","key":"2025112318514747900_bnaf020-B111","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1007\/s12020-024-03741-3","article-title":"Pharmacokinetics and pharmacodynamics of a pasireotide subcutaneous depot (CAM4071) and comparison with immediate and long-acting release pasireotide","volume":"84","author":"Johnsson","year":"2024","journal-title":"Endocrine"},{"issue":"1","key":"2025112318514747900_bnaf020-B112","doi-asserted-by":"crossref","first-page":"K8","DOI":"10.1093\/ejendo\/lvad171","article-title":"A novel somatostatin receptor ligand for human ACTH\u2014and GH -secreting pituitary adenomas","volume":"190","author":"Regazzo","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"2025112318514747900_bnaf020-B113","doi-asserted-by":"crossref","first-page":"bqae033","DOI":"10.1210\/endocr\/bqae033","article-title":"A potent neutralizing monoclonal antibody to human growth hormone suppresses insulin-like growth factor-1 in female rats","volume":"165","author":"Hata","year":"2024","journal-title":"Endocrinology"},{"issue":"1","key":"2025112318514747900_bnaf020-B114","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/cen.12797","article-title":"A paradigm shift in the medical treatment of acromegaly: from a \u2018trial and error\u2019 to a personalized therapeutic decision-making process","volume":"83","author":"Gadelha","year":"2015","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"1","key":"2025112318514747900_bnaf020-B115","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1080\/17446651.2023.2293107","article-title":"Biomarkers of response to treatment in acromegaly","volume":"19","author":"Kasuki","year":"2024","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B116","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s11102-016-0768-4","article-title":"Somatostatin receptor ligands in acromegaly: clinical response and factors predicting resistance","volume":"20","author":"Paragliola","year":"2017","journal-title":"Pituitary"},{"issue":"3","key":"2025112318514747900_bnaf020-B117","doi-asserted-by":"crossref","first-page":"R89","DOI":"10.1530\/EJE-17-1006","article-title":"MANAGEMENT OF ENDOCRINE DISEASE: personalized medicine in the treatment of acromegaly","volume":"178","author":"Kasuki","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025112318514747900_bnaf020-B118","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1530\/eje.1.02313","article-title":"Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas","volume":"156","author":"Taboada","year":"2007","journal-title":"Eur J Endocrinol"},{"issue":"7","key":"2025112318514747900_bnaf020-B119","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1210\/clinem\/dgab125","article-title":"Machine learning-based prediction model for treatment of acromegaly with first-generation somatostatin receptor ligands","volume":"106","author":"Wildemberg","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B120","first-page":"38","article-title":"Low somatostatin receptor subtype 2, but not dopamine receptor subtype 2 expression predicts the lack of biochemical response of somatotropinomas to treatment with somatostatin analogs","volume":"36","author":"Wildemberg","year":"2013","journal-title":"J Endocrinol Invest"},{"issue":"6","key":"2025112318514747900_bnaf020-B121","first-page":"580","article-title":"Validation of immunohistochemistry for somatostatin receptor subtype 2A in human somatotropinomas: comparison between quantitative real time RT-PCR and immunohistochemistry","volume":"35","author":"Wildemberg","year":"2012","journal-title":"J Endocrinol Invest"},{"issue":"1","key":"2025112318514747900_bnaf020-B122","doi-asserted-by":"crossref","first-page":"e13313","DOI":"10.1111\/bpa.13313","article-title":"Somatostatin receptors in pituitary somatotroph adenomas as predictors of response to somatostatin receptor ligands: a pathologist's perspective","volume":"35","author":"Botelho","year":"2025","journal-title":"Brain Pathol"},{"issue":"11","key":"2025112318514747900_bnaf020-B123","doi-asserted-by":"crossref","first-page":"4519","DOI":"10.1210\/jc.2008-1063","article-title":"Reassessment of sst2 somatostatin receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-1","volume":"93","author":"Fischer","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B124","doi-asserted-by":"crossref","first-page":"E66","DOI":"10.1210\/jc.2012-2609","article-title":"Immunoreactivity score using an anti-sst2A receptor monoclonal antibody strongly predicts the biochemical response to adjuvant treatment with somatostatin analogs in acromegaly","volume":"98","author":"Gatto","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B125","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.canlet.2015.01.037","article-title":"Truncated somatostatin receptor variant sst5TMD4 confers aggressive features (proliferation, invasion and reduced octreotide response) to somatotropinomas","volume":"359","author":"Luque","year":"2015","journal-title":"Cancer Lett"},{"issue":"9","key":"2025112318514747900_bnaf020-B126","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1172\/JCI119779","article-title":"Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors","volume":"100","author":"Shimon","year":"1997","journal-title":"J Clin Invest"},{"issue":"2","key":"2025112318514747900_bnaf020-B127","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1530\/EJE-15-0832","article-title":"Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study","volume":"174","author":"Iacovazzo","year":"2016","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"2025112318514747900_bnaf020-B128","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1080\/17446651.2020.1749048","article-title":"Potential markers of disease behavior in acromegaly and gigantism","volume":"15","author":"Hernandez-Ramirez","year":"2020","journal-title":"Expert Rev Endocrinol Metab"},{"issue":"5","key":"2025112318514747900_bnaf020-B129","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.tem.2012.11.007","article-title":"Novel pathway for somatostatin analogs in patients with acromegaly","volume":"24","author":"Gadelha","year":"2013","journal-title":"Trends Endocrinol Metab"},{"issue":"11","key":"2025112318514747900_bnaf020-B130","doi-asserted-by":"crossref","first-page":"E373","DOI":"10.1210\/jc.2009-2556","article-title":"Clinical characteristics and therapeutic responses in patients with germ-line AIP mutations and pituitary adenomas: an international collaborative study","volume":"95","author":"Daly","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B131","doi-asserted-by":"crossref","first-page":"L25","DOI":"10.1530\/ERC-12-0020","article-title":"AIP expression in sporadic somatotropinomas is a predictor of the response to octreotide LAR therapy independent of SSTR2 expression","volume":"19","author":"Kasuki","year":"2012","journal-title":"Endocr Relat Cancer"},{"issue":"2","key":"2025112318514747900_bnaf020-B132","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12022-008-9029-z","article-title":"Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form","volume":"19","author":"Obari","year":"2008","journal-title":"Endocr Pathol"},{"issue":"2","key":"2025112318514747900_bnaf020-B133","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1530\/EJE-13-0349","article-title":"Ki-67 is a predictor of acromegaly control with octreotide LAR independent of SSTR2 status and relates to cytokeratin pattern","volume":"169","author":"Kasuki","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"2025112318514747900_bnaf020-B134","doi-asserted-by":"crossref","first-page":"101893","DOI":"10.1016\/j.beem.2024.101893","article-title":"Predictors of biochemical response to somatostatin receptor ligands in acromegaly","volume":"38","author":"Marazuela","year":"2024","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"2","key":"2025112318514747900_bnaf020-B135","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1007\/s11102-020-01096-2","article-title":"Clinical, biological, radiological, and pathological comparison of sparsely and densely granulated somatotroph adenomas: a single center experience from a cohort of 131 patients with acromegaly","volume":"24","author":"Swanson","year":"2021","journal-title":"Pituitary"},{"issue":"5","key":"2025112318514747900_bnaf020-B136","doi-asserted-by":"crossref","first-page":"3088","DOI":"10.1111\/jcmm.13851","article-title":"E-cadherin expression is associated with somatostatin analogue response in acromegaly","volume":"23","author":"Venegas-Moreno","year":"2019","journal-title":"J Cell Mol Med"},{"issue":"2","key":"2025112318514747900_bnaf020-B137","doi-asserted-by":"crossref","first-page":"e0117107","DOI":"10.1371\/journal.pone.0117107","article-title":"Regulation of aryl hydrocarbon receptor interacting protein (AIP) protein expression by MiR-34a in sporadic somatotropinomas","volume":"10","author":"Denes","year":"2015","journal-title":"PLoS One"},{"issue":"15","key":"2025112318514747900_bnaf020-B138","doi-asserted-by":"crossref","first-page":"8653","DOI":"10.3390\/ijms23158653","article-title":"MicroRNA in acromegaly: involvement in the pathogenesis and in the response to first-generation somatostatin receptor ligands","volume":"23","author":"Henriques","year":"2022","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2025112318514747900_bnaf020-B139","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.3390\/ijms24032875","article-title":"miR-383-5p, miR-181a\u20135p, and miR-181b-5p as predictors of response to first-generation somatostatin receptor ligands in acromegaly","volume":"24","author":"Henriques","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2025112318514747900_bnaf020-B140","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1210\/jc.2014-2468","article-title":"A structural and functional acromegaly classification","volume":"100","author":"Cuevas-Ramos","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2025112318514747900_bnaf020-B141","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1530\/ERC-18-0565","article-title":"Molecular profiling for acromegaly treatment: a validation study","volume":"27","author":"Puig-Domingo","year":"2020","journal-title":"Endocr Relat Cancer"},{"issue":"1","key":"2025112318514747900_bnaf020-B142","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3390\/jcm12010025","article-title":"Resistance to somatostatin analogs in Italian acromegaly patients: the MISS study","volume":"12","author":"Berton","year":"2022","journal-title":"J Clin Med"},{"issue":"3","key":"2025112318514747900_bnaf020-B143","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1148\/radiol.2017171920","article-title":"Methodologic guide for evaluating clinical performance and effect of artificial intelligence technology for medical diagnosis and prediction","volume":"286","author":"Park","year":"2018","journal-title":"Radiology"},{"issue":"8","key":"2025112318514747900_bnaf020-B144","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.tips.2019.06.001","article-title":"The missing pieces of artificial intelligence in medicine","volume":"40","author":"Gilvary","year":"2019","journal-title":"Trends Pharmacol Sci"},{"issue":"12","key":"2025112318514747900_bnaf020-B145","doi-asserted-by":"crossref","first-page":"e4382","DOI":"10.1210\/clinem\/dgac584","article-title":"Routine evaluation of somatostatin receptor type 2 in patients with acromegaly: do we still need more evidence?","volume":"107","author":"Gatto","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"2025112318514747900_bnaf020-B146","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1530\/EJE-22-0339","article-title":"Digital quantification of somatostatin receptor subtype 2a immunostaining: a validation study","volume":"187","author":"Campana","year":"2022","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"2025112318514747900_bnaf020-B147","doi-asserted-by":"crossref","first-page":"8979","DOI":"10.1038\/s41598-022-12955-2","article-title":"Data mining analyses for precision medicine in acromegaly: a proof of concept","volume":"12","author":"Gil","year":"2022","journal-title":"Sci Rep"},{"issue":"3","key":"2025112318514747900_bnaf020-B148","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1007\/s13167-021-00246-1","article-title":"Overview of omics biomarkers in pituitary neuroendocrine tumors to design future diagnosis and treatment strategies","volume":"12","author":"Aydin","year":"2021","journal-title":"EPMA J"},{"issue":"6","key":"2025112318514747900_bnaf020-B149","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1007\/s00330-018-5876-2","article-title":"Predicting response to somatostatin analogues in acromegaly: machine learning-based high-dimensional quantitative texture analysis on T2-weighted MRI","volume":"29","author":"Kocak","year":"2019","journal-title":"Eur Radiol"},{"issue":"11","key":"2025112318514747900_bnaf020-B150","doi-asserted-by":"crossref","first-page":"2982","DOI":"10.1210\/clinem\/dgac512","article-title":"Predictive factors of somatostatin receptor ligand response in acromegaly-a prospective study","volume":"107","author":"Ilie","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"2025112318514747900_bnaf020-B151","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1210\/clinem\/dgae444","article-title":"Personalized medicine in acromegaly: the ACROFAST study","volume":"110","author":"Marques-Pamies","year":"2024","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Endocrine Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/edrv\/advance-article-pdf\/doi\/10.1210\/endrev\/bnaf020\/63730074\/bnaf020.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/6\/838\/63730074\/bnaf020.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/edrv\/article-pdf\/46\/6\/838\/63730074\/bnaf020.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T23:52:11Z","timestamp":1763941931000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/edrv\/article\/46\/6\/838\/8196836"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,11]]},"references-count":151,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2025,7,11]]},"published-print":{"date-parts":[[2025,11,24]]}},"URL":"https:\/\/doi.org\/10.1210\/endrev\/bnaf020","relation":{},"ISSN":["0163-769X","1945-7189"],"issn-type":[{"value":"0163-769X","type":"print"},{"value":"1945-7189","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,12]]},"published":{"date-parts":[[2025,7,11]]}}}